Titus Wealth Management’s AstraZeneca AZN Stock Holding History

Titus Wealth Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$225K	Buy	+1,701	New	+$223K	0.11%	142

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Titus Wealth Management's AZN Position: Q2 2022 in Review

Titus Wealth Management opened a new position in AstraZeneca (AZN) in Q2 2022: 1,701 shares worth $225K. The stake represents 0.11% of the portfolio and ranks #142 among its holdings.

1,015 funds tracked by Wall St. Rank hold AZN as of Q2 2022.

Titus Wealth Management held 1,701 shares of AstraZeneca worth $225K as of Q2 2022.
AstraZeneca was a new Titus Wealth Management position in Q2 2022.
AstraZeneca made up 0.11% of Titus Wealth Management's portfolio in Q2 2022, its #142 holding.
1,015 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2022.

Based on Titus Wealth Management's 13F filing for Q2 2022, filed 9 Nov 2022.